Cargando...
Optimized timing of using infliximab in perianal fistulizing Crohn's disease
Infliximab (IFX), as a drug of first-line therapy, can alter the natural progression of Crohn’s disease (CD), promote mucosal healing and reduce complications, hospitalizations, and the incidence of surgery. Perianal fistulas are responsible for the refractoriness of CD and represent a more aggressi...
Gardado en:
| Publicado en: | World J Gastroenterol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Baishideng Publishing Group Inc
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7167413/ https://ncbi.nlm.nih.gov/pubmed/32327905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v26.i14.1554 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|